In the overall performance analysis (Figure 6), sensitivity values varied, with the Anti-SARS-CoV-2 IgG ELISA at 51.6%, the IBMP Spike IgA/IgM/IgG ELISA and the Anti-SARS-CoV-2 NCP IgM ELISA at 60.9%, and the GOLD ELISA COVID-19 IgG/IgM at 67.2%. This evidence concerns the gene CD40LG and COVID-19.